查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464769

慢性發炎去髓鞘化多發性神經病變市場：按治療、診斷和最終用戶分類 - 全球預測 2024-2030

Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment (Corticosteroids, Intravenous Immunoglobulin (IVIG), Physiotherapy), Diagnosis (Blood & Urine Tests, Electrodiagnostic Testing, Lumbar Puncture), End-Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年慢性發炎去髓鞘化神經病變市場規模為23.5億美元，2024年達24.9億美元，2030年達34.9億美元，複合年成長率為5.81%。

慢性發炎去髓鞘化多發性神經病變 (CIDP) 是一種神經肌肉或自體免疫疾病，分類為腿部和手臂感覺功能受損。此疾病是由於免疫系統錯誤地攻擊神經的保護膜（也稱為髓鞘）引起的。結果，神經訊號傳導減慢，導致肌肉無力、反射減弱和感覺障礙。 CIDP是一種慢性疾病，也是神經病學中最重要的疾病之一，因為它對患者的生活品質有重大影響。快速識別和適當的治療性介入對於控制症狀和改善結果至關重要，這凸顯了持續研究和開發針對這種衰弱性疾病的治療方法的重要性。對神經系統疾病的日益關注以及政府支持這些疾病治療的積極努力正在推動對 CIDP 治療的需求。然而，與 CIDP 相關的高成本對製造商和最終用戶來說是一個重大挑戰。公司不斷致力於研發 (R&D)，推出新藥以在這個時代保持敏捷。此外，CIDP 診斷和治療方面的技術創新正在改善患者的治療效果並推動需求。創新研發包括開發更有效、侵入性更小的治療方法、開發用於早期準確檢測的新型診斷工具以及探索CIDP的遺傳基礎以發現新的治療標靶等。

主要市場統計
基準年[2023] 23.5億美元
預測年份 [2024] 24.9億美元
預測年份 [2030] 34.9億美元
複合年成長率（%） 5.81%

透過增加靜脈注射人類免疫球蛋白 G 治療 CIDP 的使用來改善患者預後

慢性發炎去髓鞘化多發性神經病變 (CIDP) 的治療包括一種整體方法，旨在抑制不適當的免疫反應，同時改善患者的生活品質。治療通訊協定的第一線是靜脈注射靜脈注射（IVIG），它提供調節免疫系統功能的抗體。潑尼松等皮質類固醇可以減輕發炎並調節免疫系統活力，同樣重要。血漿去除術是一種替代策略，涉及血液淨化，以去除對這些治療沒有反應的患者的有害抗體。物理治療在CIDP的綜合治療中起著至關重要的作用，其目的是維持和提高肌肉力量、靈活性和可操作性。

最終使用者：擴大 CIDP 在醫院和診所治療的可能性，使有效的治療方法更廣泛地獲得。

醫院已成為初步診斷和治療的重要設施，提供包括靜脈注射免疫球蛋白（IVIg）治療在內的全面護理，這需要專門的醫療設備和專業知識。專科診所由具有 CIDP 深入知識的專業人員提供持續管理和專業治療，提供強化治療方法。居家照護越來越受到人們的關注，以保持護理的連續性，特別是在包括皮下免疫球蛋白 (SCIg) 治療在內的長期治療中。這些設定中的每一種都提供不同的益處並滿足 CIDP 患者群體的特定需求，確保廣泛獲得有效的治療方法。

區域洞察

在美洲，特別是在美國和加拿大，對 CIDP 的認知和診斷不斷增加，對有效治療的需求也在增加。以患者為中心的醫療保健系統和高購買力推動了客戶對創新治療方法的強烈購買行為。龐大的研發投資和有利的醫療政策正在支持 CIDP 市場的成長。 FDA 最近核准了 CIDP 治療，證實了該地區對解決這種使人衰弱的疾病的承諾。另一方面，歐盟 (EU) 國家在 CIDP 認知、診斷和治療取得方面存在不同的情況。歐盟的醫療體系優先考慮公平獲取，包括 CIDP 在內的不同國家採取了不同的模式來支持罕見疾病治療。最近的歐盟範圍內的舉措著重於加強研究、簡化監管途徑和促進跨境醫療合作，旨在改善整個歐洲大陸的病患治療效果。由於醫療保健支出的增加和診斷能力的提高，中國、日本和印度等亞太國家在 CIDP 市場中正在迅速發展。日本是一個醫療保健技術先進且注重研究的地區，大量的專利和臨床試驗證明了這一點。中國和印度因其人口眾多以及對包括 CIDP 在內的自體免疫疾病的認知不斷提高而成為重要市場。

FPNV定位矩陣

FPNV定位矩陣對於評估慢性發炎去髓鞘化多發性神經病變市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對發炎去髓鞘化多發性神經病變市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.慢性發炎去髓鞘化多發性神經病變市場的市場規模與預測是多少？

2.在慢性發炎去髓鞘化神經病變市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.慢性發炎去髓鞘化多發性神經病變市場的技術趨勢和法規結構是什麼？

4.發炎去髓鞘化神經病變市場主要供應商的市場佔有率為何？

5.進入慢性發炎去髓鞘化多發性神經病變市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 自體免疫和神經系統疾病在全世界日益受到關注
      • 擴大罕見疾病的醫療保健費用和保險範圍
      • 政府對 CIDP 治療的有利舉措和核准
    • 抑制因素
      • CIDP 治療相關的高費用
    • 機會
      • 正在進行的研究旨在了解 CIDP 的病理並開發新的治療方法
      • CIDP 診斷和治療的持續創新改善了患者的治療效果
    • 任務
      • 由於症狀與其他神經肌肉疾病相似而誤診或延遲診斷
  • 市場區隔分析
    • 治療：在 CIDP 治療中增加人類靜脈注射免疫球蛋白 G 的使用，以改善患者預後
    • 最終用途：擴大 CIDP 治療在醫院和診所的可用性，以確保更廣泛地獲得有效的治療方法
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章慢性發炎去髓鞘化多發性神經病變市場的治療

  • 皮質類固醇
  • 靜脈注射免疫球蛋白 (IVIG)
  • 物理治療
  • 血漿置換

第7章慢性發炎去髓鞘化多發性神經病變診斷市場

  • 血液和尿液檢查
  • 電診斷測試
  • 腰椎穿刺

第8章慢性發炎去髓鞘化多發性神經病變市場：依最終用途分類

  • 家庭護理設置
  • 醫院
  • 專科診所

第9章美洲慢性發炎性脫髓鞘去髓鞘化神經病變市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區發炎去髓鞘化多發性神經病變市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的慢性發炎去髓鞘化多發性神經病變市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 武田的 HYQVIA 獲歐盟委員會核准作為 CIDP 患者的維持治療
    • 武田製藥的 HYQVIA 獲得 FDA核准用於治療 CIDP
    • 再鼎醫藥艾法莫德注射（皮下注射）在中國獲得針對慢性發炎去髓鞘化多發性神經病變患者的突破性治療認定
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-F97DD5A7D581

[187 Pages Report] The Chronic Inflammatory Demyelinating Polyneuropathy Market size was estimated at USD 2.35 billion in 2023 and expected to reach USD 2.49 billion in 2024, at a CAGR 5.81% to reach USD 3.49 billion by 2030.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neuromuscular or autoimmune disorder categorized by impaired sensory function in the legs and arms. The condition stems from the immune system mistakenly attacking the protective covering of the nerves, also known as the myelin sheath. This leads to slow nerve signal conduction, causing muscle weakness, reflex loss, and sensory problems. CIDP is paramount in neurology due to its chronic nature and significant impact on patient's quality of life. Rapid identification and appropriate therapeutic intervention are crucial in managing the symptoms and improving outcomes, highlighting the importance of ongoing research and development in treatments targeting this debilitating disorder. The rising concerns about neurological disorders and favorable government initiatives to support the treatment of these disorders propel the demand for CIDP treatment. However, the high cost associated with the CIDP is a significant challenge for the manufacturers and end users. Companies are constantly working towards research and development (R&D) and introducing novel drugs to remain agile within the landscape. Moreover, the Innovations in diagnostics and therapeutics for CIDP improve patient outcomes, thereby driving demand. Innovation and research include the development of more effective and less invasive treatment methods, novel diagnostic tools for early and accurate detection, and exploring the genetic basis of CIDP to uncover new therapeutic targets.

KEY MARKET STATISTICS
Base Year [2023] USD 2.35 billion
Estimated Year [2024] USD 2.49 billion
Forecast Year [2030] USD 3.49 billion
CAGR (%) 5.81%

Treatment: Increasing usage of human intravenous immunoglobulin G in CIDP treatment to cater better patient outcomes

Chronic inflammatory demyelinating polyneuropathy (CIDP) management encompasses a holistic approach designed to dampen the improper immune reaction while enhancing the patient's quality of life. At the forefront of treatment protocols is administering intravenous immunoglobulin (IVIG), which supplies antibodies to adjust the immune system's functionality. Corticosteroids such as prednisone, which alleviate inflammation and modulate the immune system's vigor, are equally critical. Plasmapheresis represents an alternative strategy involving blood purification to eliminate deleterious antibodies for patients unresponsive to these treatments. Integral to the treatment regimen, physiotherapy aims to preserve and improve muscle strength, suppleness, and operational capacity, thereby playing an indispensable role in the comprehensive care approach for CIDP.

End-Use: Widening availability of CIDP treatment in hospitals and clinics to ensure broader accessibility to effective treatment regimens

Hospitals emerge as key facilities for initial diagnosis and treatment, providing comprehensive care, including intravenous immunoglobulin (IVIg) therapy, which demands specialized medical equipment and expertise. Specialty clinics offer a focused approach, catering to ongoing management and specialized treatments with professionals with in-depth knowledge of CIDP. Homecare settings are gaining prominence in maintaining the continuum of care, especially for long-term treatments, including subcutaneous immunoglobulin (SCIg) therapy, allowing patients comfort and convenience while minimizing hospital visits. Each of these settings offers distinct advantages and caters to the specific needs of the CIDP patient population, ensuring broader accessibility to effective treatment regimens.

Regional Insights

In the Americas, particularly the United States and Canada, there is a growing awareness and diagnosis rate of CIDP, driving demand for effective treatments. Patient-centric healthcare systems and high purchasing power produce strong customer purchasing behavior for innovative therapies. Significant R&D investments, coupled with favorable healthcare policies, support the growth of the CIDP market. Recent FDA approvals for CIDP treatments underscore the region's commitment to addressing this debilitating condition. On the other hand, European Union (EU) countries show a diverse landscape regarding CIDP awareness, diagnosis, and treatment access. Healthcare systems in the EU prioritize equitable access, with various countries adopting different models, including CIDP, to support rare disease treatments. Recent EU-wide initiatives focus on enhancing research, streamlining regulatory pathways, and fostering cross-border healthcare cooperation, aiming to improve patient outcomes across the continent. Asia Pacific countries such as China, Japan, and India are rapidly evolving in the CIDP market space, driven by increasing healthcare spending and improving diagnostic capabilities. Japan is in the region with advanced healthcare technologies and a strong focus on research, demonstrated by the high volume of patents and clinical trials. China and India are significant markets due to their large populations and growing awareness of autoimmune diseases, including CIDP.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Chronic Inflammatory Demyelinating Polyneuropathy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Chronic Inflammatory Demyelinating Polyneuropathy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Chronic Inflammatory Demyelinating Polyneuropathy Market, highlighting leading vendors and their innovative profiles. These include Avalon Pharma Pvt Ltd., Baxter International, Inc., Biotest AG, CSL Limited, F. Hoffmann-La Roche Ltd., Green Cross Corporation, Grifols, S.A., Johnson & Johnson Services, Inc., Kedrion Biopharma, Lee BioSolutions, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Viatris Inc., and Zai Lab Limited.

Market Segmentation & Coverage

This research report categorizes the Chronic Inflammatory Demyelinating Polyneuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Corticosteroids
    • Intravenous Immunoglobulin (IVIG)
    • Physiotherapy
    • Plasmapheresis
  • Diagnosis
    • Blood & Urine Tests
    • Electrodiagnostic Testing
    • Lumbar Puncture
  • End-Use
    • Homecare Settings
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Chronic Inflammatory Demyelinating Polyneuropathy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Chronic Inflammatory Demyelinating Polyneuropathy Market?

3. What are the technology trends and regulatory frameworks in the Chronic Inflammatory Demyelinating Polyneuropathy Market?

4. What is the market share of the leading vendors in the Chronic Inflammatory Demyelinating Polyneuropathy Market?

5. Which modes and strategic moves are suitable for entering the Chronic Inflammatory Demyelinating Polyneuropathy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing concerns for autoimmune and neurological disorders worldwide
      • 5.1.1.2. Higher healthcare expenditure and insurance coverage for rare diseases
      • 5.1.1.3. Favorable government initiatives and approvals for CIDP treatment
    • 5.1.2. Restraints
      • 5.1.2.1. The high cost associated with CIDP treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research into understanding the pathophysiology of CIDP and the development of new treatments
      • 5.1.3.2. Continuous innovations in diagnostics and therapeutics for CIDP to improve patient outcomes
    • 5.1.4. Challenges
      • 5.1.4.1. Misdiagnosis or delayed diagnosis due to symptom similarity with other neuromuscular disorders
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Increasing usage of human intravenous immunoglobulin G in CIDP treatment to cater better patient outcomes
    • 5.2.2. End-Use: Widening availability of CIDP treatment in hospitals and clinics to ensure broader accessibility to effective treatment regimens
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment

  • 6.1. Introduction
  • 6.2. Corticosteroids
  • 6.3. Intravenous Immunoglobulin (IVIG)
  • 6.4. Physiotherapy
  • 6.5. Plasmapheresis

7. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Diagnosis

  • 7.1. Introduction
  • 7.2. Blood & Urine Tests
  • 7.3. Electrodiagnostic Testing
  • 7.4. Lumbar Puncture

8. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End-Use

  • 8.1. Introduction
  • 8.2. Homecare Settings
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Chronic Inflammatory Demyelinating Polyneuropathy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Takeda's HYQVIA Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 12.3.2. Takeda's HYQVIA Wins FDA Approval for CIDP Therapy
    • 12.3.3. Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET DYNAMICS
  • FIGURE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN (IVIG), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN (IVIG), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY BLOOD & URINE TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY BLOOD & URINE TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ELECTRODIAGNOSTIC TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ELECTRODIAGNOSTIC TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY LUMBAR PUNCTURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY LUMBAR PUNCTURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 57. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 58. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 63. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 64. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 71. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 72. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 86. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 91. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 92. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 97. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 98. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 103. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 104. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 109. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 110. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 115. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 116. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 122. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 127. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 128. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 134. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 139. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 140. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 145. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 146. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 151. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 152. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 165. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 166. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 171. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 172. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 177. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 178. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 183. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 184. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 189. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 190. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 195. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 196. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 201. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 202. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 208. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 213. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 214. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 219. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 220. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 225. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 226. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 231. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 232. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 237. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 238. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 244. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 255. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 256. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 261. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 262. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 268. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET S